Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 Sep-Oct;43(5):308-314.
doi: 10.5144/0256-4947.2023.308. Epub 2023 Oct 5.

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey

Ahmet Sahin  1 , Ozlem Akay  2
Affiliations
Observational Study

Experience with direct-acting antivirals in genotype 1-5 infected chronic hepatitis C patients in Turkey

Ahmet Sahin et al. Ann Saudi Med. 2023 Sep-Oct.

Abstract

Background: Hepatitis C virus (HCV) can cause chronic liver disease, hepatic cirrhosis, hepatocellular carcinoma, liver transplantation, and death. Early diagnosis and treatment are thus vital.

Objectives: We aimed to investigate the sustained virological response (SVR) rates in chronic hepatitis C patients infected with different genotypes, receiving different direct-acting antiviral treatments (DAAs).

Design: Retrospective, observational SETTING: Clinic for infectious diseases and clinical microbiology PATIENTS AND METHODS: Patients diagnosed with chronic hepatitis C who applied to our outpatient clinic between January 2016 and November 2022 and were treated with a DAA were included in the study. Treatment responses were evaluated after each patient was treated with either ledipasvir plus sofosbuvir (LDV/SOF), LDV/SOF + ribavirin (RBV), SOF+RBV, ombitasvir/paritaprevir/ritonavir plus dasabuvir (OBV/PTV/r±DSV) ±RBV, or glecaprevir plus pibrentasvir (GLE/PIB).

Main outcome measures: Sustained virological response (SVR) rates at 12 weeks (SVR12) post-treatment.

Sample size: 360 patients.

Results: Of 360 patients who met the inclusion criteria, 218 (60.6%) were male and 142 (39.4%) were female with no statistically significant differences in SVR between sexes (P=.252). Nearly all had a SVR (n=353, 98.1%). The median (IQR) age of the patients was 56 (30.3) years. There were 42 (11.7%), 199 (55.3%), 4 (1.1%), 106 (29.4%), 8 (2.2%) and 1 (0.3%) patient with genotypes 1a, 1b, 2, 3, 4 and 5, respectively, and SVR12 did not differ significantly between genotypes (P=.066). SVR12 response was higher in 246 (68.3%) non-injecting drug users compared to 114 (31.7%) injecting drug users (P=.005). The SVR12 response was achieved in 100% of patients with genotypes 1a, 2, 4, and 5. SVR12 response could not be obtained in 1 of 199 genotype 1b patients and 6 of 106 genotype 3 patients. The common feature of 6 reinfection patients with genotype 3 was that they were using intravenous drugs. These 6 patients were reinfected due to their continued intravenous drug use.

Conclusion: In conclusion, DAAs provide high SVR12 rates in cirrhotic/non-cirrhotic, pegylated interferon-naive/experienced patient groups and in patients infected with all genotypes. DAAs have a high SVR12 rate in patients with chronic hepatitis C.

Limitations: Retrospective, single-center.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST: None.

Similar articles

See all similar articles

References

    1. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415. Epub 20220216. doi: 10.1016/s2468-1253(21)00472-6. PubMed PMID: 35180382. - DOI - PubMed
    1. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. .. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020–6. Epub 20150708. doi: 10.1016/j.cmi.2015.06.028. PubMed PMID: 26163105. - DOI - PubMed
    1. Yuri Y, Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, et al. .. Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis. J Clin Med. 2019;9(1). Epub 20191230. doi: 10.3390/jcm9010095. PubMed PMID: 31905953; PubMed Central PMCID: PMC7019884. - DOI - PMC - PubMed
    1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. .. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28. doi: 10.1056/NEJMoa1013086. PubMed PMID: 21696308. - DOI - PubMed
    1. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. .. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206. doi: 10.1056/NEJMoa1010494. PubMed PMID: 21449783; PubMed Central PMCID: PMC3766849. - DOI - PMC - PubMed

Publication types